Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

Although β-blockers have been endorsed by guidelines committees for the treatment of
patients with hypertension, particularly those with significant CVD and high CVD risk, there …

New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …

We tested the activity of nebivolol, a β 1-selective blocker with respect to nitric oxide (NO)
and peroxynitrite (ONOO−) generation in the endothelium of normotensive Wistar Kyoto …

Nebivolol is a β1-receptor antagonist with vasodilator and antioxidant properties. Because
the vascular NADPH oxidase is an important superoxide source, we studied the effect of …

Long-term nitric oxide blockade by N ω-nitro-l-arginine methyl ester (L-NAME) leads to
severe and progressive hypertension. The role of salt intake in this model is unclear. To …

The endothelium is a favourite early target of cardiovascular risk factors and cardiovascular
diseases like hypertension. This key role of the endothelium results from its capacity to …

Background. Nitric oxide (NO) deficiency contributes to chronic kidney disease (CKD)
progression and hypertension. The β-blocker, nebivolol (N), also enhances NO production …

Nitric oxide (NO) is a tonically produced vasodilator that maintains blood pressure (BP) in
the normal animal. In these studies, we produced chronic NO blockade by oral …

Nebivolol, unlike other selective β1-receptor blockers, induces vasodilation attributable to
increased NO bioavailability. The relative contribution of this mechanism to the blood …